OCC-WCC 2024 | WCC結構性心臟病治療的創新探索：雲端研討，共創未來！
*僅供醫學專業人士閱讀參考
會議時間：2024年6月27-30日
會議地點：上海國際會議中心
第十八屆東方心臟病學會議（The 18th Oriental Congress of Cardiology，OCC 2024）與世界心臟病學大會（World Congress of Cardiology，WCC 2024）將於2024年6月27日至30日在上海國際會議中心盛大開幕。
作為領域備受矚目的盛會，這兩大會議匯聚了全球頂尖的專家學者，共同探討心血管疾病的最新研究成果、治療技術和未來發展趨勢。特別是在結構性心臟病這一重要分支上，與會者將深入交流最新的臨床資料和研究成果，共同推動該領域的研究和治療向前邁進。
The 18th Oriental Congress of Cardiology (OCC 2024) and the World Congress of Cardiology (WCC 2024) will be grandly held at the Shanghai International Convention Center from June 27 to 30, 2024.
As highly anticipated events in the field of cardiology, these two conferences will gather top experts and scholars from around the world to discuss the latest research findings, treatment techniques, and future development trends in cardiovascular diseases. Specifically, in the crucial subfield of structural heart disease, participants will engage in in-depth exchanges on the latest clinical data and research outcomes, jointly advancing research and treatment in this area.
論壇時間：2024年6月29日 星期六
論壇地點：上海國際會議中心3CD
論壇壇主：新加坡國家心臟中心Jack Tan教授；浙江大學醫學院附屬第二醫院王建安院士
Forum Date:Saturday,June 29 2024 ；
Forum Venue: 3CD，Shanghai International Conference Centre
Forum Chairs:
Professor Jack Tan, National Heart Centre Singapore;
Professor Wang Jianan, The Second Affiliated Hospital, School of Medicine, Zhejiang University.
Jack Tan教授
王建安院士
心臟瓣膜病
Heart valve disease
在全球範圍內，心臟瓣膜病的治療需求日益增加，這不僅是因為人口老齡化帶來的自然增長，更是因為醫療技術的進步使得越來越多的患者能夠從中受益。
南非的Liesl Zuhkle教授將以其深厚的專業知識和豐富的臨床經驗，為我們詳細闡述心臟瓣膜病的全球需求，以及當前結構性心臟病領域在影像學和治療技術上的實際考慮與創新。
The treatment demand for heart valve diseases is increasing globally, not only due to the natural growth brought by the aging population, but also because medical technology advances enable more and more patients to benefit from them.
Professor Liesl Zuhkle from South Africa will elaborate on the global demand for heart valve diseases, as well as the practical considerations and innovations in imaging and treatment technologies in the current field of structural heart diseases, with her profound professional knowledge and rich clinical experience.
二尖瓣修復技術
Mitral valve repair technology
談及結構性心臟病的治療時，二尖瓣修復技術無疑是其中一顆璀璨的明星。二尖瓣作為心臟中至關重要的瓣膜之一，其健康狀態直接關係到心臟的正常執行。一旦二尖瓣受損或功能失調，就可能導致嚴重的心臟疾病。
在這一重要領域，泰國胸外科醫師協會的主席 Taweesak Chotivatanapong教授將以其豐富的臨床經驗和專業知識，與我們分享關於二尖瓣修復的寶貴經驗，引領我們探索更多關於二尖瓣治療的新知識。
When discussing the treatment of structural heart diseases, mitral valve repair technology undoubtedly stands out as a brilliant star. The mitral valve, one of the crucial valves in the heart, directly relates to the normal functioning of the heart. Any impairment or malfunction of the mitral valve can lead to severe heart diseases.
In this significant field, Professor Taweesak Chotivatanapong from Thailand will share his valuable experience in mitral valve repair, drawing from his rich clinical expertise and professional knowledge. He will guide us to explore more new knowledge about mitral valve treatment.
中國力量，勇於創新
Chinese Strength, Courageous in Innovation!
在結構性心臟病的治療領域，技術的創新是推動治療進展的關鍵力量。復旦大學附屬中山醫院的潘文志教授將深入探討單純主動脈瓣反流經股動脈TAVR（經導管主動脈瓣置換術）在中國的創新實踐，這一突破性的技術不僅充分展現了中國在結構性心臟病治療領域的尖端實力，而且為患者提供了更為安全、高效的治療方案。
與此同時，醫學院附屬第一人民醫院的陸方林教授將聚焦於中國三尖瓣反流介入治療器械的創新成果。三尖瓣反流作為一種常見的結構性心臟病，其治療技術的創新同樣至關重要。陸教授將分享中國在這一領域取得的顯著進展，這些創新不僅為患者提供了更多樣化、個性化的治療選擇，更是中國醫療技術不斷髮展、突破自我的重要標誌。
In the field of structural heart disease treatment, technological innovation is the key force driving progress. Professor Pan Wenzhi from Zhongshan Hospital, Fudan University, will delve into the innovative practice of Transcatheter Aortic Valve Replacement (TAVR) via femoral artery for pure aortic regurgitation in China. This breakthrough technology not only fully demonstrates Chinas cutting-edge strength in the field of structural heart disease treatment, but also provides patients with a safer and more efficient treatment plan.
At the same time, Professor Lu Fanglin from the First Peoples Hospital affiliated to Shanghai Jiao Tong University School of Medicine will focus on the innovative achievements in interventional treatment devices for tricuspid regurgitation in China. As a common structural heart disease, the innovation of treatment techniques for tricuspid regurgitation is equally crucial. Professor Lu will share Chinas significant progress in this field, which not only provides patients with more diverse and personalized treatment options, but also marks the continuous development and self-breakthrough of Chinese medical technology.
我們熱切期盼著即將召開的WCC結構性心臟病論壇。此次論壇的盛大召開，無疑預示著結構性心臟病治療領域即將迎來嶄新的突破與無限的機遇。全球頂尖的專家學者將共同探索結構性心臟病治療的前沿技術，分享寶貴的臨床經驗，為患者提供更加精準、高效的治療方案。讓我們攜手共進，為結構性心臟病的治療領域注入新的活力，為患者帶來福音！
We eagerly anticipate the upcoming WCC-Structural Heart Disease Forum. The grand opening of this forum undoubtedly heralds new breakthroughs and boundless opportunities in the field of structural heart disease treatment. Top global experts and scholars will jointly explore cutting-edge technologies in structural heart disease treatment, share valuable clinical experiences, and provide patients with more precise and effective treatment plans. Lets work together to inject new vitality into the field of structural heart disease treatment and bring blessings to patients!
歡迎註冊
會議時間：2024年6月27-30日
會議地點：上海國際會議中心
註冊官網：www.occmd.org
Conference Dates：June 27-30, 2024
Conference Venue：Shanghai International Convention Center
Registration Website：www.occmd.org
更多心血管精彩內容
快來“醫生站網頁版”瞧一瞧
精彩資訊等你來
*"醫學界"力求所發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在採用或以此作為決策依據時另行核查。